Prevention of Adult Caries Study (PACS)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

983 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adult tooth decay is an infectious disease that afflicts the majority of Americans aged 55 and older and is the most common chronic disease at midlife with an ever growing economic toll. Despite the fact that specific bacteria cause tooth decay, no FDA-approved anti-microbial treatment for decay is available to the American dental professional. The Prevention of Adult Caries Study (PACS) is a study designed to evaluate the efficacy of a topical, temporary, 10% w/v chlorhexidine dental coating in reducing new decay in adult dental patients at risk for decay.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Manual Toothbrushes in Removing Tooth Stains

NCT06486974

Tooth Discoloration

RECRUITING PHASE3

Domiciliary Professional Oral Care for Dependent Older Adults

NCT05335239

Dental Caries of Root Surface Aging

COMPLETED NA

Reducing Risk for Infective Endocarditis

NCT05721781

Bacteremia Infective Endocarditis

RECRUITING NA

NAC Prevents Toxicity of Teeth Bleaching

NCT03534115

Removal of Toxicity From Dental Bleaching

COMPLETED EARLY_PHASE1

Preventing and Arresting Dental Root Surface Caries in Community-dwelling Older Adults

NCT02360124

Dental Caries

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Prevention of Adult Caries Study (PACS) is a randomized, double-blind, placebo-controlled Phase III clinical trial conducted under F.D.A. Investigational New Drug license #45,466, with a target enrollment of 1000 at four clinical centers with vastly different populations. The centers participating in this proposed research are: Kaiser Permanente's Dental Plan in Portland, Oregon; Tufts University Dental Clinic in central Boston, Massachusetts; Delta Dental Massachusetts' Dental Clinic in Southborough, Massachusetts; and the dental clinic of the Tuba City Regional Health Care Corporation in Tuba City, Arizona. Kaiser Permanente's Center for Health Research in Portland, Oregon will act as the data-coordinating center, and Tufts University will act as the Administrative Center. This study is designed to evaluate the efficacy of a topical, temporary, 10% w/v chlorhexidine dental coating in reducing caries increment in at-risk adult dental patients. This study will treat participants in months 1(4 weekly applications) and 7(1 application) with final outcome measured at 13 months after randomization. Examiners were trained and certified before data collection started and were recalibrated annually. The primary outcome analysis in the intent -to- treat sample compares active to placebo group on the rank-normalized caries increment score, adjusting for examiner, age and age squared. Multiple imputation (data augmentation using MCMC) will be used to replace missing outcome. Planned secondary analysis examine the secondary caries increment outcomes using the same model, as well as parallel analyses in the per-protocol group. Safety of the coating will be evaluated by comparing development of resistant S. mutans or C. albicans as well as incidence of MedDRA-coded adverse events between the two arms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Caries, Dental

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo Dental Coating

Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Active Dental Coating

10% w/v chlorhexidine acetate coating FDA IND #45466. Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition

Group Type ACTIVE_COMPARATOR

10% w/v chlorhexidine acetate coating FDA IND #45466

Intervention Type DRUG

Dental coating topically applied by dental professional supragingivally to the full dentition

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

10% w/v chlorhexidine acetate coating FDA IND #45466

Dental coating topically applied by dental professional supragingivally to the full dentition

Intervention Type DRUG

Placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CHX

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age and older
* at least 20 intact natural teeth, excluding third molars
* 2 or more lesions, of which at least one must be a cavitated D2 or D3
* willing and able to provide informed consent

Exclusion Criteria

* pregnant or planning to become pregnant or planning to become pregnant during the study (breastfeeding is permitted)
* use of fixed orthodontic appliances
* allergic to any of the ingredients of the study medication
* long-term antibiotic therapy
* a history of, or currently active, radiation therapy for cancers of the head or neck
* Sjögren's syndrome
* advanced periodontitis
* consumption of the equivalent of more than five servings of acidic or sugared drinks per day
* having 10 or more lesions requiring restorative care at the time of the screening visit
* remineralization therapy within one month of randomization
* investigator discretion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No